IDEXX Laboratories (IDXX) Stock Forecast & Price Target

$534.28 +2.97 (+0.56%)

As of 10:27 AM Eastern

IDEXX Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
0

Hold
3

Buy
6

Based on 9 Wall Street analysts who have issued ratings for IDEXX Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 3 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for IDXX.

Consensus Price Target

$546.00
2.19% Upside

According to the 9 analysts' twelve-month price targets for IDEXX Laboratories, the average price target is $546.00. The highest price target for IDXX is $580.00, while the lowest price target for IDXX is $510.00. The average price target represents a forecasted upside of 2.19% from the current price of $534.29.

Get the Latest News and Ratings for IDXX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors.

IDXX Analyst Ratings Over Time

Type	Current Forecast 6/30/24 to 6/30/25	1 Month Ago 5/31/24 to 5/31/25	3 Months Ago 4/1/24 to 4/1/25	1 Year Ago 7/1/23 to 6/30/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$546.00	$536.00	$533.75	$586.63
Forecasted Upside	2.19% Upside	4.58% Upside	27.52% Upside	20.41% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

IDXX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IDXX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IDEXX Laboratories Stock vs. The Competition

Type	IDEXX Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.78	2.81	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	2.84% Upside	8,543.25% Upside	12.42% Upside
News Sentiment Rating	Positive News See Recent IDXX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/11/2025	Leerink Partners 1 of 5 stars	Daniel Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$515.00 ➝ $580.00	+11.06%
5/19/2025	Stifel Nicolaus 4 of 5 stars	Jonathan Block Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$460.00 ➝ $510.00	-1.36%
5/5/2025	Morgan Stanley 3 of 5 stars	Erin Wright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$548.00 ➝ $558.00	+19.13%
2/10/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Westenberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$435.00 ➝ $510.00	+10.01%
2/4/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Balaji Prasad Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$481.00 ➝ $520.00	+10.86%
2/4/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Ryskin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$475.00 ➝ $535.00	+14.06%
12/2/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/11/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$630.00 ➝ $575.00	+20.64%
7/25/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Massaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$580.00	+23.05%
4/9/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
Get the Latest News and Ratings for IDXX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.
1/17/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$500.00 ➝ $650.00	+25.68%
12/7/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$602.00	+15.42%
8/2/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$610.00	+14.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:27 AM ET.

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 29, 2025. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDEXX Laboratories
Bull Case

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

The current stock price is around $531, reflecting a recent increase, which may indicate positive market sentiment towards the company.
IDEXX Laboratories, Inc. has shown consistent revenue growth, with a reported quarterly revenue increase of 3.6% compared to the same period last year, suggesting strong demand for its products.
The company has a high return on equity of 57.35%, indicating effective management and profitability, which can be attractive to investors looking for strong financial performance.
Analysts have a consensus rating of "Moderate Buy" for IDEXX Laboratories, Inc., with several recent upgrades in price targets, suggesting confidence in the company's future performance.
Institutional investors own a significant portion of the company’s stock (87.84%), which can be a positive indicator of stability and investor confidence in the company's long-term prospects.

IDEXX Laboratories
Bear Case

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

The stock has a relatively high P/E ratio of 49.03, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
Despite recent growth, the company faces competition in the veterinary diagnostics market, which could impact its market share and profitability in the future.
The debt-to-equity ratio of 0.31, while not excessively high, indicates that the company does carry some debt, which could be a concern if interest rates rise or if the company faces financial challenges.
Recent downgrades from some analysts, including a shift from a "buy" to a "hold" rating, may signal caution among market experts regarding the stock's short-term performance.
Market volatility can affect stock prices, and IDEXX Laboratories, Inc. is not immune to broader market trends that could negatively impact its stock value.

IDXX Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for IDEXX Laboratories is $546.00, with a high forecast of $580.00 and a low forecast of $510.00.
: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 3 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IDXX shares.
: According to analysts, IDEXX Laboratories's stock has a predicted upside of 2.19% based on their 12-month stock forecasts.
: IDEXX Laboratories has been rated by research analysts at Leerink Partners, Morgan Stanley, and Stifel Nicolaus in the past 90 days.
: Analysts like IDEXX Laboratories less than other "medical" companies. The consensus rating score for IDEXX Laboratories is 2.78 while the average consensus rating score for "medical" companies is 2.81. Learn more on how IDXX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:IDXX) was last updated on 6/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEXX Laboratories (IDXX) Stock Forecast & Price Target